Impact of Perioperative Shedding of the Endothelial Glycocalyx on the Incidence of Postoperative Acute Kidney Injury in Patients Undergoing Valvular Heart Surgery.
NCT ID: NCT03197051
Last Updated: 2019-01-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
250 participants
OBSERVATIONAL
2017-06-25
2018-07-11
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In cases of cardiac surgery, patients cannot help but be exposed to ischemia/reperfusion, oxidative stress which can damage endothelial glycocalyx. In this research, the investigators would like to discover the impact of perioperative shedding of the endothelial glycocalyx on the incidence of postoperative acute kidney injury in patients undergoing valvular heart surgery.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
In Vivo Glycocalyx as Predictor of Complications After Cardiac Surgery
NCT04643535
Vascular Events In Patients Undergoing Same-day Noncardiac Surgery (VALIANCE) Study
NCT04973397
Renal Function in Patients Submitted to Myocardial Revascularization Surgery
NCT00905775
Damage and Renal Clearance of Glycocalyx in Cardiac Surgery
NCT04332952
Perioperative Endothelial Dysfunction
NCT02344771
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Postoperative acute kidney injury up to postoperative 48 hours, Composite morbidity and mortality up to postoperative 30 days will be checked.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Q1
Measure the Concentration of Syndecan-1, Heparan sulfate before anesthetic induction and immediately after weaning from cardiopulmonary bypass. Categorize the patients by serum syndecan-1 concentration(off-CPB) quartile. Q1 means a group of lowest 25% of serum syndecan-1 concentration.
No interventions assigned to this group
Q2
Q2 means a group of lower 25\~50% of serum syndecan-1 concentration.
No interventions assigned to this group
Q3
Q3 means a group of higher 50\~75% of serum syndecan-1 concentration.
No interventions assigned to this group
Q4
Q4 means a group of highest 75\~100% of serum syndecan-1 concentration.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Aorta surgery (Graft replacement of Total arch or Descending thoracic aorta)
* Minimal invasive surgery
* Chronic kidney disease (eGFR\<30mL/min/1.73m2) / Dialysis history
* Infective endocarditis
* Malignancy
* Patients who cannot give Informed consent (e.g. Illiterate, Foreigners)
* Patients who are already enrolled to another study than can affect the results
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Yonsei University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Anesthesiology and Pain Medicine, Yonsei University College of Medicine
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
4-2017-0340
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.